Finoriq research workspace
AMGEN INC (AMGN) SEC Filings & Filing Highlights
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Review AMGN SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
- Company
- AMGEN INC (AMGN)
- Ticker
- AMGN
- Market Cap
- $197.1B
- Latest Price
- $365.2
- Industry
- Biotech & Pharma
AMGEN INC (AMGN) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for AMGEN INC (AMGN).
| Event | Form | Date |
|---|---|---|
| The Company held its Annual Meeting on May 19, 2026. The final results of the voting for each m...The Company held its Annual Meeting on May 19, 2026. The final results of the voting for each matter submitted to a vote of stockholders at... | 8-K5.07 | 2026-05-20 |
| Retirement of Peter H. Griffith, Chief Financial Officer On May 19, 2026, Amgen Inc. (the “Comp...Retirement of Peter H. Griffith, Chief Financial Officer On May 19, 2026, Amgen Inc. (the “Company”) publicly announced that Peter H. Griff... | 8-K5.02 | 2026-05-19 |
| AMGEN INC: Material agreementOn February 17, 2026, Amgen Inc. (the “Company”) issued and sold $1,000,000,000 aggregate principal amount of the Company’s 4.200% Senior N... | 8-K1.01 | 2026-02-19 |
| Fourth Quarter and Full Year 2025 Earnings Press Release and Reconciliation of Non-GAAP Financi...Fourth Quarter and Full Year 2025 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures | 8-K2.02 | 2026-02-03 |
| AMGEN INC: Agreement terminationOn January 30, 2026, Amgen Inc. (the “Company”) entered into a Termination Agreement (the “Termination Agreement”) with Kyowa Kirin Co., Lt... | 8-K1.02 | 2026-01-30 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.